Introduction {#Sec1}
============

Patients with diabetes are at high risk of hospitalization, which is three-fold greater than patients without diabetes \[[@CR1]\]. It is reported that around 30% of patients with type 2 diabetes mellitus (T2DM) had been hospitalized in 1 year \[[@CR2]\]. However, reasons for hospitalization are diverse, including chronic complications of diabetes, infection, cardiovascular disease, hypoglycemia, etc. \[[@CR3], [@CR4]\]. In such patients, aside from disease leading to hospitalization, diabetes management is important. Uncontrolled hyperglycemia or hypoglycemia is associated with poor hospital outcomes including prolonged hospital stay, increased ICU admission rate, even increased mortality rate \[[@CR5]--[@CR8]\]. As a result, the goal of diabetes management in hospitalized patients is to minimize the impact of hyperglycemia on the disease which leads to hospitalization, prevent hypoglycemia, and ensure a smooth transition to outpatient treatment.

Basal insulin, NPH or insulin glargine, is the most commonly used regimen in diabetes management in hospital, together with mealtime insulin or oral antihyperglycemic drugs. Compared to NPH-based regimen, insulin glargine-based regimen is associated with lower rate of symptomatic hypoglycemia, nocturnal hypoglycemia, and severe hypoglycemia \[[@CR9], [@CR10]\]. Therefore, insulin glargine is more popular in the management of diabetes among inpatients mainly due to the reduction of hypoglycemia events and related hospital costs.

Two versions of insulin glargine are available in China at present: the brand insulin glargine (Lantus, Sanofi, Germany) and the biosimilar insulin glargine (Basalin, Gan & Lee, China). Both versions of insulin glargine have been available since 2005 in China, and gradually replaced NPH usage in outpatients and inpatients in the past decade \[[@CR11]\]. The biosimilar insulin glargine has a lower price than the brand insulin glargine. But direct comparisons of efficacy and safety between the two versions of insulin glargine are limited and controversial. A pharmacologic study has shown bioequivalence of Lantus and Basalin in Chinese healthy volunteers \[[@CR12]\]. But in our previously conducted retrospective analysis, switching from the biosimilar insulin glargine to the brand insulin glargine was associated with further reductions in blood glucose, without dose increasing \[[@CR13]\].

To compare the efficacy and safety of treatment with brand and biosimilar basal insulin, we did a propensity score matched, retrospective analysis in non-critical hospitalized patients with T2DM, because these patients required high-quality glycemic control, which meant achieving and maintaining normoglycemia (FBG 6.1--7.8 mmol/L) without hypoglycemia.

Methods {#Sec2}
=======

Data Source {#Sec3}
-----------

This was a retrospective study using the electronic medical records (EMRs) of patients hospitalized at the Qingdao Endocrine and Diabetes Hospital (the Hospital) in China, from January 2006 to December 2017. Detailed information of the hospital and patients was previously published \[[@CR14]\]. In general, the hospital is a public, non-profit, tertiary hospital specializing in the management of diabetes. Patients were admitted to the hospital mainly as a result of uncontrolled hyperglycemia, including persistent hyperglycemia, newly diagnosed diabetic patients with HbA1c \> 9% or FPG \> 11 mmol/L, diabetic ketoacidosis, diabetic hyperosmolality, etc., and worsening of chronic complication, including coronary heart disease, diabetic neuropathy, diabetic retinopathy, etc. Non-critical patients defined as patients treated with subcutaneous injection of basal insulin, together with or without mealtime insulin or oral antihyperglycemic drugs, aimed to achieve normoglycemia (FBG 6.1--7.8 mmol/L) without hypoglycemia. Brand selection of basal insulin (Lantus or Basalin) was based on patients insurance coverage, patients affordability, and patients' insulin accessibility after discharge.

The data selection process for the current study is summarized in Fig. [1](#Fig1){ref-type="fig"}. EMRs were initially searched using the keywords "Lantus," "Basalin," or "insulin glargine" to identify patients with recorded use of insulin glargine during hospitalization. The following exclusion criteria were then applied: treatment with basal insulin other than insulin glargine, switching insulin therapy during hospitalization; critically ill patients (acute diabetic complications, diabetic coma caused by hypoglycemia, diabetes comorbid with infection, severe renal or hepatic impairment), age \< 18 years; no confirmed T2DM diagnosis; or adequate glycemic control (FBG ≤ 7 mmol/L) at hospital admission.Fig. 1Data selection pathway. *EMR* electronic medical record, *FBG* fasting blood glucose, *T2DM* type 2 diabetes mellitus

The first day of subcutaneous injection of basal insulin was defined as the start of treatment (baseline), while the day of discharge was defined as the end of treatment. Hypoglycemia was defined as any recorded incidence of blood glucose (BG) ≤ 3.9 mmol/L, and severe hypoglycemia was defined as requiring assistance from others to administrate carbohydrates, glucagon, or other resuscitative actions, with or without BG ≤ 3.0 mmol/L.

The study was approved by the hospital ethical committee and all procedures were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Definition of Clinical Outcomes {#Sec4}
-------------------------------

The efficacy outcomes of this analysis were change in fasting blood glucose (FBG) from start to end of basal insulin treatment, final FBG value, change in daily glucose profile (measured at seven points of glucose, namely fasting, at time of each meal and 2 h post each meal, and at bedtime) from start to end of basal insulin treatment, dose of basal insulin at treatment end, duration of basal insulin treatment, and duration of hospitalization.

The safety outcome of this analysis was the incidence of hypoglycemia.

Statistical Methods {#Sec5}
-------------------

Data were analyzed and reported using SAS software (v.9.4). Propensity score matching was conducted using Proc PSMATCH in SAS software (v.9.4). Each propensity score included the following explanatory variables at baseline of treatment which could potentially be related to any confounding effect on BG values independent of basal insulin treatments: age, gender, BMI, diabetes duration, treatment regimen, number of oral antidiabetic drugs (OADs), history of cardiovascular disease, history of smoking, history of diabetic complications, HbA1c and FBG at admission, starting dose of basal insulin (Table [1](#Tab1){ref-type="table"}). Matching was conducted to minimize selection biases which might confound comparisons between basal insulin treatments. Matched explanatory variables in the current logistic model included gender, age, HbA1c and FBG at baseline, diabetes duration. The difference in the logit of the propensity score (LPS) was selected as the statistic for matching subjects in two treatment groups. All available observations were selected and a greedy nearest neighbor matching algorithm matched the Basalin to the Lantus cohort by 1:3 without replacement. Matching used a default caliper width of 0.25 times the standard deviation of the estimated LPSs. A sensitivity analysis was also conducted using 1:1 and 1:2 matching, individually. Mean change in FBG from baseline was compared between the two treatment groups before and after matching, as well as mean changes in seven-point BG profiles.Table 1Patient baseline characteristicsPre-matchingPost-matching 1:3Basalin, *n* = 47Lantus, *n* = 429*p*Basalin, *n* = 34Lantus, *n* = 101*p*Age, years61.53 (10.37)62.99 (12.08)0.4361.91 (10.84)61.57 (11.96)0.88Males, *n* (%)19 (40.4)239 (55.7)0.0611 (32.4)37 (36.6)0.68BMI, (kg/m^2^)27.12 (3.86)27.05 (15.90)0.9427.25 (3.39)29.32 (32.12)0.52Diabetes duration, years8.11 (4.98)11.30 (6.67)\< 0.018.53 (5.12)8.22 (4.75)0.75Treatment regimen Basal insulin + OAD(s)27 (57.4)279 (65.0)0.3420 (58.8)60 (59.4)1.00 Basal insulin + prandial insulin20 (42.6)150 (35.0)14 (41.2)41 (40.6)Number of OADs 020 (42.6)150 (35.0)0.2814 (41.2)41 (40.6)0.51 16 (12.8)64 (14.9)5 (14.7)11 (10.9) 27 (14.9)122 (28.4)4 (11.8)25 (24.8) 310 (21.3)69 (16.1)8 (23.5)14 (13.9) 44 (8.5)22 (5.1)3 (8.8)9 (8.9) 502 (0.5)01 (1.0)History of cardiovascular disease, *n* (%)19 (40.4)207 (48.3)0.3615 (44.1)48 (47.5)0.84History of smoking, *n* (%)14 (29.8)165 (38.5)0.277 (20.6)29 (28.7)0.50History of diabetic complications, *n* (%)43 (91.5)416 (97.0)0.0831 (91.2)98 (97.0)0.17HbA1c at admission, (%)8.37 (1.91)7.98 (1.65)0.198.31 (1.89)8.32 (1.98)0.97FBG, (mmol/L)9.64 (2.72)9.14 (1.96)0.239.44 (2.37)9.46 (2.25)0.96Starting dose of basal insulin, (IU/kg)0.19 (0.07)0.19 (0.07)0.720.20 (0.06)0.19 (0.07)0.30*BMI* body mass index, *FBG* fasting blood glucose*p* values calculated using a Student's *t* test for continuous variables and Chi-square test for categorical variables

Continuous variables are presented as mean (standard deviation, SD), and discrete variables are summarized as frequency and percentage. Pre- and post-matching, treatment differences between the Basalin and Lantus groups were assessed using either Student's *t* test or Chi-square test, depending on each variables' properties. A *p* value less than 0.05 was considered statistically significant. All analyses were conducted using SAS software (version 9.4).

Results {#Sec6}
=======

Patient Characteristics {#Sec7}
-----------------------

A total of 47 patients treated with Basalin and 429 treated with Lantus met the study criteria and were eligible for matching. There were remarkable differences between these unmatched treatment groups at baseline in terms of their mean duration of diabetes (8.1 months vs. 11.3 months; *p* \< 0.01) and the proportion of male patients (40.4% vs. 55.7%; *p* = 0.06) (Table [1](#Tab1){ref-type="table"}). After matching, differences in seven-point BG values were minimized between two treatment groups at baseline (Table [2](#Tab2){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}a).Table 2Baseline seven-point blood glucosePre-matchingPost-matchingBasalin, *n* = 47Lantus, *n* = 429*p*Basalin, *n* = 34Lantus, *n* = 101*p*FBG9.64 (2.72)9.14 (1.96)0.239.44 (2.37)9.46 (2.25)0.96Post-breakfast BG12.24 (3.48)11.72 (3.34)0.3312.18 (2.74)12.21 (3.85)0.95Pre-lunch BG10.51 (4.36)10.13 (3.14)0.619.84 (3.56)10.14 (3.36)0.69Post-lunch BG11.62 (3.69)11.07 (3.37)0.3011.26 (3.08)10.90 (3.70)0.62Pre-dinner BG9.55 (3.77)9.42 (3.20)0.819.31 (3.36)9.42 (3.25)0.88Post-dinner BG11.24 (3.54)11.24 (3.26)1.0010.97 (3.30)10.99 (3.44)0.98Pre-bedtime BG10.29 (3.54)10.10 (3.21)0.7210.06 (3.40)10.44 (3.30)0.59*BMI* body mass index, *FPG* fasting plasma glucose*p* values calculated using a Student's *t* testFig. 2Seven-point blood glucose measurements **a** at baseline before and after 1:3 propensity score matching, **b** at baseline and after treatment after 1:3 propensity score matching, and **c** change in blood glucose measurements from hospitalization to end of treatment, for patients with T2DM treated with Basalin or Lantus. Dotted lines represent patients who received Basalin, solid lines represent patients who received Lantus

After propensity score matching, the 1:3 matched cohorts included 34 patients who had received Basalin and 101 patients who received Lantus (Table [1](#Tab1){ref-type="table"}). As expected, there were no statistically significant differences between the two groups at the post-matching baseline.

Changes in Blood Glucose {#Sec8}
------------------------

Post-matching, patients who received Lantus achieved a significantly greater mean reduction in FBG from baseline to end of treatment versus those who received Basalin (− 2.20 mmol/L vs. − 1.24 mmol/L; *p* = 0.04) (Fig. [3](#Fig3){ref-type="fig"}). The mean FBG value at the end of treatment was numerically lower for patients treated with Lantus versus those treated with Basalin (7.26 mmol/L vs. 8.20 mmol/L; *p* = 0.12).Fig. 3**a** Mean change in FBG from baseline to end of treatment, **b** mean FBG at end of treatment, and **c** mean insulin dose at end of treatment, for patients with T2DM treated with Basalin or Lantus. *FBG* fasting blood glucose, *IU* international units, *T2DM* type 2 diabetes

Changes in mean seven-point BG profiles between baseline and end of treatment were observed in both the Basalin and Lantus treatment groups (Fig. [2](#Fig2){ref-type="fig"}b). Patients treated with Lantus showed a trend towards lower mean post-breakfast and pre-lunch BG levels compared with those receiving Basalin, although these differences did not reach statistical significance (Table [2](#Tab2){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}c).

Insulin Dose and Duration of Treatment {#Sec9}
--------------------------------------

There was no significant difference in the daily dose of basal insulin between the Basalin and Lantus groups at baseline (0.19 vs. 0.18 IU/kg; *p* = 0.30) or end of treatment (0.21 vs. 0.21 IU/kg; *p* = 0.99). Similarly, the duration of basal insulin treatment (16.4 vs. 15.3 days; *p* = 0.74) and length of hospitalization (19.5 vs. 17.7 days; *p* = 0.60) were comparable between the matched groups.

Safety {#Sec10}
------

The incidence of hypoglycemia was low and comparable between patients who received Basalin and Lantus; hypoglycemia occurred in one versus four patients, respectively (*p* = 1.00). No patient in either group experienced a severe hypoglycemic event and no other adverse events were recorded.

Sensitivity Analysis {#Sec11}
--------------------

A sensitivity analysis comparing outcomes for matched cohorts of Basalin/Lantus patient ratios of 1:1 and 1:2 showed similar results as for the main 1:3 analysis (Table [3](#Tab3){ref-type="table"}).Table 3Summary of basal insulin treatment and outcomesPre-matchingPost-matching 1:1Post-matching 1:2Post-matching 1:3Basalin, *n* = 47Lantus, *n* = 429*p*Basalin, *n* = 34Lantus, *n* = 34*p*Basalin, *n* = 34Lantus, *n* = 68*p*Basalin, *n* = 34Lantus, *n* = 101*p*Change in FBG− 1.85 (3.09)− 1.87 (2.21)0.97− 1.24 (2.70)− 2.67 (2.33)0.02− 1.24 (2.70)− 2.33 (2.39)0.04− 1.24 (2.70)− 2.20 (2.22)0.04Final FBG, (mmol/L)7.79 (2.86)7.28 (1.87)0.248.20 (3.21)7.22 (1.67)0.128.20 (3.21)7.11 (1.72)0.078.20 (3.21)7.26 (2.01)0.12Final dose of basal insulin, (IU)14.66 (5.79)14.63 (6.11)0.9814.94 (5.00)15.35 (6.58)0.7714.94 (5.00)15.35 (6.15)0.7414.94 (5.00)14.89 (6.38)0.97Final dose of basal insulin, (IU/kg)0.21 (0.10)0.20 (0.09)0.460.21 (0.07)0.22 (0.08)0.770.21 (0.07)0.22 (0.08)0.690.21 (0.07)0.21 (0.08)0.99Length of basal insulin treatment15.0 (17.6)16.1 (11.8)0.6616.4 (20.4)15.3 (7.9)0.7616.4 (20.4)14.7 (7.4)0.6416.4 (20.4)15.3 (7.8)0.74Length of hospitalization18.1 (17.3)18.3 (12.3)0.9219.5 (20.0)17.9 (7.5)0.6719.5 (20.0)17.5 (7.6)0.5819.5 (20.0)17.7 (7.8)0.60Hypoglycemia, *n*2140.671NullNull13 (4.4)Null141.00*FBG* fasting blood glucose*p* values calculated using a Student's *t* test

Discussion {#Sec12}
==========

To our knowledge, this study is the first comparison of the efficacy of brand and biosimilar insulin glargine in hospitalized patients with diabetes. We found that the brand insulin glargine (Lantus) treatment was associated with greater reduction in mean FBG, at a similar final insulin dose and with a similarly low incidence of hypoglycemia, compared with the biosimilar insulin glargine (Basalin) in this propensity score matched retrospective analysis in non-critical hospitalized patients. In addition, patients who received Lantus also showed a trend towards greater reductions in post-breakfast and pre-lunch BG compared with those receiving Basalin, although these treatment differences did not reach statistical significance.

Hyperglycemia control was important for hospitalized patients. A previous randomized controlled trial had demonstrated that, among hospitalized patients, compared to a mean FBG of 8.5 mmol/L in the conventional-treatment group, the intensive-treatment group reduced FBG to 5.7 mmol/L, resulting in a significant in-hospital mortality reduction from 10.9% to 7.2% (absolute risk reduction, 3.7%). Moreover, the lower FBG level was also associated with a 46% reduction of bloodstream infections and 41% reduction of acute renal failure requiring dialysis or hemofiltration \[[@CR15]\]. A subsequent observational study also showed a J-curve association between blood glucose level and mortality risk, with the nadir roughly between 5 and 8 mmol/L \[[@CR16]\]. All the results pointed out a clear goal for glycemic control in hospitalized patients, and implied that maintaining blood glucose levels as close to normal as possible would improve clinical outcomes. Therefore, the magnitude of the difference in FBG improvement between the Lantus and Basalin treatments in this analysis (absolute difference 0.96 mmol/L) is clinically meaningful. Indeed, we observed that length of basal insulin treatment and length of hospital stay were numerically lower with Lantus treatment, although there were no statistically significant differences between the two treatments. This might be because the matched sample size is too small to detect a difference between the two treatments.

Hypoglycemia is strongly associated with adverse outcomes in non-critical hospitalized patients \[[@CR8], [@CR17]\]. To avoid the risk of hypoglycemia, current guidelines recommended a less stringent blood glucose goal (7.8--10.0 mmol/L) for hospitalized patients, and the goal range of 6.1--7.8 mmol/L was only recommended to selected patients at low risk of hypoglycemia \[[@CR18]\]. In our hospital, each patient was assessed at admission to determine if his/her condition was critical. Non-critical patients were then assigned to antihyperglycemia treatment, and accurate and frequent blood glucose measurements were performed to detect if any trend showing blood glucose levels dropped too low. In this analysis, only five out of 135 non-critical patients experienced hypoglycemia, and the incidence of hypoglycemia was comparable between two treatment (*p* = 1.00). No patient in either group experienced a severe hypoglycemic event.

Insulin glargine is a basal insulin widely used in diabetes management. Nowadays, more biosimilar insulin glargine came to market. However, insulin has a narrow therapeutic window and a need for accuracy of dosing to ensure an optimum balance between efficacy and safety \[[@CR19]\]. Though biosimilar insulin glargine had shown bioequivalent profiles to originator insulin glargine \[[@CR12]\], concerns were still raised about their clinical efficacy and additional adverse effects. It is therefore necessary to evaluate the similarity of clinical efficacy and safety of the biosimilar insulin glargine to brand insulin glargine. Such comparison data will provide more references for physicians in their clinical decision-making.

In this retrospective analysis, all non-critical hospitalized patients received similar antihyperglycemic treatment and targeted at the same glycemic range. Propensity score matching was conducted to minimized interferences on blood glucose results. On the basis of such background, we found that, compared to biosimilar insulin glargine, brand insulin glargine was associated with a higher FBG reduction without increased hypoglycemia risk at a similar final insulin dose. These results implied that biosimilar insulin glargine probably had lower potency than the originator insulins in a real clinical setting.

The limitations of this study include the short duration of treatment and the single-center setting. As patients prefer to choose premixed insulin because of its relatively lower price and convenience of injection, many patients with basal insulin-based regimens during hospitalization were switched to premixed insulin-based regimens several days before discharge. Therefore, the number of patients treated with basal insulin-based regimens was limited as lots of subjects were excluded as a result of insulin regimen switching. To make the comparison more valid, we employed the procedure of propensity score matching to control potential selection bias due to non-random treatment allocation and to minimize the effect of confounding factors, such as duration of diabetes, proportion of male patients, HbA1c and BG levels at admission, etc.

Conclusions {#Sec13}
===========

In real-life clinical practice, injection of the brand insulin glargine, Lantus, provided better fasting glycemic control compared to biosimilar insulin glargine, Basalin, without increased hypoglycemia risk at a similar insulin dose. Further investigation in a randomized controlled trial is required before changes to treatment practice can be advocated.
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